Health-care companies were flat, hovering near all-time highs amid optimism about the biotech and obesity-drug niches. In the first head-to-head test, Eli Lilly's Zepbound obesity drug helped people ...
New data indicating Eli Lilly’s obesity shot Zepbound works better than Novo Nordisk’s Wegovy could add fuel to Lilly’s new ...
Eli Lilly said Wednesday its obesity drug Zepbound spurred more weight loss than Novo Nordisk's Wegovy in the first-ever head ...
More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...
The randomized clinical trial showed that Zepbound patients achieved 47% more relative weight loss than Wegovy patients.
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...
Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.
Zepbound's greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of the weight loss drug market.
Lilly's Zepbound outperforms Novo Nordisk's Wegovy in weight loss study, boosting market-share gains and stock prices.
The major ones include Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro and Zepbound. But competitors, including ...
People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a clinical ...
Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, ...